Immuneering Corporation reported its financial results for the first quarter ended March 31, 2025, on May 5, 2025. The company highlighted that IMM-1-104 demonstrated exceptional efficacy for patients with pancreatic cancer, including a third-line monotherapy patient with over 13 months progression-free survival, a second-line monotherapy patient with a confirmed partial response, and a first-line combination therapy patient with a confirmed complete response.
The company reiterated the encouraging overall response rates and disease control rates for IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer, which were reported in January. Progression-free survival data from more than 30 patients with first-line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 is planned for announcement in the second quarter of 2025.
Immuneering also announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo (cemiplimab) in non-small cell lung cancer. The company named Dr. Igor Matushansky as Chief Medical Officer and stated that its cash runway has been extended into 2026, as it ramps up planning for a Phase 3 trial in first-line pancreatic cancer patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.